Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Trauner, M; Halilbasic, E; Kazemi-Shirazi, L; Kienbacher, C; Staufer, K; Traussnigg, S; Hofer, H.
Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Dig Dis. 2014; 32(5):631-636
Doi: 10.1159/000360517
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Trauner Michael
- Co-Autor*innen der Med Uni Graz
- Halilbasic Emina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Chronic inflammatory bile duct diseases such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) result in progressive fibrosis of the biliary tract and ultimately cirrhosis of the liver. Since the etiology and pathogenesis of these fibrosing cholangiopathies are still poorly understood, therapeutic options are rather limited at present. Ursodeoxycholic acid (UDCA) is the paradigm therapeutic bile acid and established standard treatment for PBC, but its role for medical therapy of PSC is still under debate. Promising novel bile acid-based therapeutic options include 24-norursodeoxycholic acid, a side chain-shortened C23 homologue of UDCA, and bile acid receptor/farnesoid X receptor agonists (e.g., obeticholic acid) which currently undergo clinical development for fibrosing cholangiopathies such as PBC and PSC. Other nuclear receptors such as vitamin D receptor and fatty acid-activated peroxisome proliferator-activated receptors are also of considerable interest. This review article is a summary of an overview talk given at Falk Symposium 191 on Advances in Pathogenesis and Treatment of Liver Diseases held in London, October 3-4, 2013, and summarizes the recent progress with novel therapeutic bile acids and bile acid derivatives as novel therapies for fibrosing cholangiopathies such as PBC and PSC.
- Find related publications in this database (using NLM MeSH Indexing)
- Bile Acids and Salts - therapeutic use
- Cholangitis, Sclerosing - drug therapy
- Humans -
- Ligands -
- Receptors, Cytoplasmic and Nuclear - agonists
- Receptors, Cytoplasmic and Nuclear - metabolism
- Ursodeoxycholic Acid - analogs & derivatives
- Ursodeoxycholic Acid - therapeutic use
- Find related publications in this database (Keywords)
- Bile acids
- Nuclear receptor agonists
- Fibrosing cholangiopathies
- 24-norUrsodeoxycholic acid
- Primary biliary cirrhosis
- Primary sclerosing cholangitis